A detailed history of California Public Employees Retirement System transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, California Public Employees Retirement System holds 890,108 shares of BMRN stock, worth $62 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
890,108
Previous 1,105,016 19.45%
Holding current value
$62 Million
Previous $96.5 Million 24.07%
% of portfolio
0.05%
Previous 0.07%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$74.43 - $92.22 $16 Million - $19.8 Million
-214,908 Reduced 19.45%
890,108 $73.3 Million
Q1 2024

Apr 30, 2024

SELL
$83.81 - $99.0 $3.74 Million - $4.42 Million
-44,660 Reduced 3.88%
1,105,016 $96.5 Million
Q4 2023

Feb 01, 2024

SELL
$76.22 - $98.51 $997,491 - $1.29 Million
-13,087 Reduced 1.13%
1,149,676 $111 Million
Q3 2023

Nov 02, 2023

SELL
$85.07 - $94.48 $388,599 - $431,584
-4,568 Reduced 0.39%
1,162,763 $103 Million
Q2 2023

Aug 09, 2023

SELL
$86.68 - $100.3 $1.73 Million - $2.01 Million
-19,996 Reduced 1.68%
1,167,331 $101 Million
Q1 2023

May 12, 2023

SELL
$87.74 - $117.27 $4.03 Million - $5.39 Million
-45,962 Reduced 3.73%
1,187,327 $115 Million
Q4 2022

Feb 08, 2023

SELL
$80.93 - $108.63 $7.42 Million - $9.96 Million
-91,719 Reduced 6.92%
1,233,289 $128 Million
Q3 2022

Nov 09, 2022

SELL
$82.16 - $96.94 $567,972 - $670,146
-6,913 Reduced 0.52%
1,325,008 $112 Million
Q2 2022

Aug 10, 2022

SELL
$71.48 - $86.85 $2.29 Million - $2.78 Million
-31,985 Reduced 2.35%
1,331,921 $110 Million
Q1 2022

May 04, 2022

SELL
$74.28 - $92.69 $2.24 Million - $2.8 Million
-30,166 Reduced 2.16%
1,363,906 $105 Million
Q4 2021

Feb 10, 2022

SELL
$71.72 - $91.47 $697,620 - $889,728
-9,727 Reduced 0.69%
1,394,072 $123 Million
Q3 2021

Nov 10, 2021

BUY
$74.77 - $85.47 $8.03 Million - $9.18 Million
107,359 Added 8.28%
1,403,799 $109 Million
Q2 2021

Aug 13, 2021

BUY
$75.51 - $84.79 $28.2 Million - $31.7 Million
373,727 Added 40.5%
1,296,440 $108 Million
Q1 2021

May 14, 2021

SELL
$74.73 - $90.69 $968,426 - $1.18 Million
-12,959 Reduced 1.38%
922,713 $69.7 Million
Q4 2020

Feb 02, 2021

BUY
$72.61 - $90.2 $1.87 Million - $2.32 Million
25,688 Added 2.82%
935,672 $82 Million
Q3 2020

Nov 05, 2020

BUY
$71.87 - $131.03 $7.07 Million - $12.9 Million
98,374 Added 12.12%
909,984 $69.2 Million
Q2 2020

Aug 12, 2020

BUY
$79.55 - $124.22 $32.7 Million - $51 Million
410,530 Added 102.36%
811,610 $100 Million
Q1 2020

May 12, 2020

SELL
$71.37 - $96.85 $1.71 Million - $2.32 Million
-23,966 Reduced 5.64%
401,080 $33.9 Million
Q4 2019

Jan 27, 2020

BUY
$64.27 - $86.37 $4.94 Million - $6.64 Million
76,834 Added 22.07%
425,046 $35.9 Million
Q3 2019

Oct 31, 2019

BUY
$67.4 - $85.11 $5.21 Million - $6.57 Million
77,246 Added 28.51%
348,212 $23.5 Million
Q2 2019

Aug 15, 2019

SELL
$80.35 - $93.9 $816,114 - $953,742
-10,157 Reduced 3.61%
270,966 $23.2 Million
Q1 2019

May 03, 2019

BUY
$84.2 - $98.62 $2.53 Million - $2.97 Million
30,066 Added 11.98%
281,123 $25 Million
Q4 2018

Feb 08, 2019

SELL
$80.14 - $106.07 $1.91 Million - $2.52 Million
-23,800 Reduced 8.66%
251,057 $21.4 Million
Q3 2018

Nov 13, 2018

SELL
$93.92 - $105.72 $2.27 Million - $2.56 Million
-24,212 Reduced 8.1%
274,857 $26.7 Million
Q2 2018

Aug 15, 2018

SELL
$76.01 - $99.03 $3.57 Million - $4.66 Million
-47,031 Reduced 13.59%
299,069 $28.2 Million
Q1 2018

May 11, 2018

SELL
$77.67 - $92.63 $1.29 Million - $1.54 Million
-16,600 Reduced 4.58%
346,100 $28.1 Million
Q4 2017

Feb 06, 2018

BUY
$80.76 - $95.13 $2.44 Million - $2.87 Million
30,200 Added 9.08%
362,700 $32.3 Million
Q3 2017

Nov 15, 2017

BUY
$80.6 - $94.95 $26.8 Million - $31.6 Million
332,500
332,500 $30.9 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.9B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track California Public Employees Retirement System Portfolio

Follow California Public Employees Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California Public Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California Public Employees Retirement System with notifications on news.